Are amplifying RNA vaccines the way forward for CAR-T-cell therapy?
Cancer Immunology and Immunotherapy

Are amplifying RNA vaccines the way forward for CAR-T-cell therapy?

Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required 

Read more
New immunotherapies are explored to improve the treatment of solid tumours
Cancer Immunology and Immunotherapy

New immunotherapies are explored to improve the treatment of solid tumours

From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed

Read more

Don't miss

  • Welcome session and Keynote Award 2021 lecture
    8 December 2021, 12:30-13:00
  • Proffered Paper session I
    9 December 2021, 09:00-10:30
  • Proffered Paper session II
    10 December 2021, 09:00-10:30

EDITORIAL

ESMO IMMUNO-ONCOLOGY AWARD

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.